UB Paderborn / Katalog / Suche / in CDI

IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis

Clinical immunology (Orlando, Fla.), 2017-01, Vol.174, p.63-72

2017

Volltextzugriff (PDF)

Electronic Pneumatic Injection‐Assisted Dermal Drug Delivery Visualized by Ex Vivo Confocal Microscopy

Lasers in surgery and medicine, 2021-01, Vol.53 (1), p.141-147

2021

Volltextzugriff (PDF)

Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo‐Controlled, Phase II Trial

Clinical and translational science, 2020-09, Vol.13 (5), p.994-1003

2020

Volltextzugriff (PDF)

Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study

Acta dermato-venereologica, 2018-07, Vol.98 (7), p.648-654

2018

Volltextzugriff (PDF)

Analysis and visualization of the course and burden over time of adverse drug reactions (ADRs) attributed to TNFα-inhibitors in patients with inflammatory rheumatic diseases (IRDs)

Expert opinion on drug safety, 2023-03, Vol.22 (3), p.195-202

2023

Volltextzugriff (PDF)

Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis

Acta dermato-venereologica, 2022-08, Vol.102, p.adv00755-adv00755

2022

Volltextzugriff (PDF)

Omiganan Enhances Imiquimod‐Induced Inflammatory Responses in Skin of Healthy Volunteers

Clinical and translational science, 2020-05, Vol.13 (3), p.573-579

2020

Volltextzugriff (PDF)

Inter- and Intra-patient Variability Over Time of Lesional Skin Microbiota in Adult Patients with Atopic Dermatitis

Acta dermato-venereologica, 2020-01, Vol.100 (1), p.adv00018-2

2020

Volltextzugriff (PDF)

Treatment of a refractory allergic reaction to a red tattoo on the lips with methotrexate and Q-switched Nd-Yag laser

JAAD Case Reports, 2022-03, Vol.21, p.109-111

2022

Volltextzugriff (PDF)

Cold-induced urticaria associated with type I cryoglobulinemia, successfully treated with rituximab

JAAD Case Reports, 2022-01, Vol.19, p.18-20

2022

Volltextzugriff (PDF)

Macular arteritis in an HIV-infected patient improving with adherence to antiretroviral therapy

JAAD Case Reports, 2020-08, Vol.6 (8), p.716-718

2020

Volltextzugriff (PDF)

Familial multiple discoid fibromas: A look-alike of Birt-Hogg-Dubé syndrome not linked to the FLCN locus

Journal of the American Academy of Dermatology, 2012-02, Vol.66 (2), p.259.e1-259.e9

2012

Volltextzugriff (PDF)

Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial

Journal of the American Academy of Dermatology, 2019-01, Vol.80 (1), p.80-88

2019

Volltextzugriff (PDF)

Personalized omalizumab treatment improves clinical benefit in patients with chronic spontaneous urticaria

Journal of allergy and clinical immunology, 2018-12, Vol.142 (6), p.1992-1994

2018

Volltextzugriff (PDF)

OX40L Inhibition Suppresses KLH‐driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof‐of‐Pharmacology for KY1005

Clinical pharmacology and therapeutics, 2022-05, Vol.111 (5), p.1121-1132

2022

Volltextzugriff (PDF)

Blueprint for mechanistic, data‐rich early phase clinical pharmacology studies in dermatology

British journal of clinical pharmacology, 2020-06, Vol.86 (6), p.1011-1014

2020

Volltextzugriff (PDF)

Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: A Randomized Controlled Trial in a real-world setting

Journal of the American Academy of Dermatology, 2023-10, Vol.89 (4), p.677-684

2023

Volltextzugriff (PDF)

Needle‐free jet injection‐induced small‐droplet aerosol formation during intralesional bleomycin therapy

Lasers in surgery and medicine, 2022-04, Vol.54 (4), p.572-579

2022

Volltextzugriff (PDF)

Complement Activation in Inflammatory Skin Diseases

Frontiers in immunology, 2018-04, Vol.9, p.639-639

2018

Volltextzugriff (PDF)

A randomized controlled trial with a delayed‐type hypersensitivity model using keyhole limpet haemocyanin to evaluate adaptive immune responses in man

British journal of clinical pharmacology, 2021-04, Vol.87 (4), p.1953-1962

2021

Volltextzugriff (PDF)

Clinical endpoints of needle‐free jet injector treatment: An in depth understanding of immediate skin responses

Lasers in surgery and medicine, 2022-07, Vol.54 (5), p.693-701

2022

Volltextzugriff (PDF)

Is methotrexate safe for men with an immune-mediated inflammatory disease and an active desire to become a father? Results of a prospective cohort study (iFAME-MTX)

Annals of the rheumatic diseases, 2023-08, Vol.82 (8), p.1068

2023

Volltextzugriff (PDF)

Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial

International journal of molecular sciences, 2023-09, Vol.24 (18), p.14315

2023

Volltextzugriff (PDF)

Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trial

Journal of the American Academy of Dermatology, 2022-04, Vol.86 (4), p.854-862

2022

Volltextzugriff (PDF)

Lesional skin of seborrheic dermatitis patients is characterized by skin barrier dysfunction and correlating alterations in the stratum corneum ceramide composition

Experimental dermatology, 2024-01, Vol.33 (1), p.e14952-n/a

2024

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis

Electronic Pneumatic Injection‐Assisted Dermal Drug Delivery Visualized by Ex Vivo Confocal Microscopy

Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo‐Controlled, Phase II Trial

Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study

Analysis and visualization of the course and burden over time of adverse drug reactions (ADRs) attributed to TNFα-inhibitors in patients with inflammatory rheumatic diseases (IRDs)

Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis

Omiganan Enhances Imiquimod‐Induced Inflammatory Responses in Skin of Healthy Volunteers

Inter- and Intra-patient Variability Over Time of Lesional Skin Microbiota in Adult Patients with Atopic Dermatitis

Treatment of a refractory allergic reaction to a red tattoo on the lips with methotrexate and Q-switched Nd-Yag laser

Cold-induced urticaria associated with type I cryoglobulinemia, successfully treated with rituximab

Macular arteritis in an HIV-infected patient improving with adherence to antiretroviral therapy

Familial multiple discoid fibromas: A look-alike of Birt-Hogg-Dubé syndrome not linked to the FLCN locus

Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial

Personalized omalizumab treatment improves clinical benefit in patients with chronic spontaneous urticaria

OX40L Inhibition Suppresses KLH‐driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof‐of‐Pharmacology for KY1005

Blueprint for mechanistic, data‐rich early phase clinical pharmacology studies in dermatology

Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: A Randomized Controlled Trial in a real-world setting

Needle‐free jet injection‐induced small‐droplet aerosol formation during intralesional bleomycin therapy

Complement Activation in Inflammatory Skin Diseases

A randomized controlled trial with a delayed‐type hypersensitivity model using keyhole limpet haemocyanin to evaluate adaptive immune responses in man

Clinical endpoints of needle‐free jet injector treatment: An in depth understanding of immediate skin responses

Is methotrexate safe for men with an immune-mediated inflammatory disease and an active desire to become a father? Results of a prospective cohort study (iFAME-MTX)

Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial

Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trial

Lesional skin of seborrheic dermatitis patients is characterized by skin barrier dysfunction and correlating alterations in the stratum corneum ceramide composition

Suchergebnisse filtern